How does omaveloxolone affect exposure to rosuvastatin?

In clinical studies in healthy subjects using omaveloxolone 150 mg, co-administration reduced rosuvastatin exposure (AUC) by approximately 30%, indicating that omaveloxolone is a weak inducer of BCRP.